Belite Bio Announces Late-Breaking Presentation At The American Academy Of Ophthalmology 2022 Annual Meeting
Belite Bio, Inc (NASDAQ:BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, today announced that the 1-year interim data from the 2-year Phase